| 高克非,冯艳玲,黄永文.三氧化二砷联合抗坏血酸对高转移性卵巢癌细胞系HO-8910PM的抗肿瘤实验研究[J].中国肿瘤,2014,23(6):518-522. |
| 三氧化二砷联合抗坏血酸对高转移性卵巢癌细胞系HO-8910PM的抗肿瘤实验研究 |
| The Research on Anti-cancer Effect of Arsenic Trioxide Combined with Ascorbic Acid on Highly Metastatic Ovarian Carcinoma Cell line HO-8910PM |
| 投稿时间：2013-11-02 |
| DOI：10.11735/j.issn.1004-0242.2014.06.A016 |
|
 |
| 中文关键词: 三氧化二砷 抗坏血酸 化疗 卵巢癌 |
| 英文关键词:arsenic trioxide ascorbic acid chemotherapy ovarian carcinoma |
| 基金项目: |
|
| 摘要点击次数: 2024 |
| 全文下载次数: 1085 |
| 中文摘要: |
| 摘 要：［目的］ 在高转移性上皮性卵巢癌细胞株HO-8910PM中观察AS2O3联合抗坏血酸（Vitamin C）的抗肿瘤效应。［方法］ 本研究以高转移性上皮性卵巢癌细胞株HO-8910PM为研究对象，以MTT药敏实验、流式细胞仪以及Western-blot方法检测AS2O3和Vitamin C单药及联合的抗肿瘤效应及其机制。［结果］ AS2O3和Vitamin C单药对HO-8910PM细胞株均具有剂量依赖性的生长抑制作用。AS2O3 联合Vitamin C后具有明显的协同抗肿瘤效应，并且出现S期阻滞效应。Western-blot结果显示，AS2O3和Vitamin C联合作用后，凋亡抑制蛋白bcl-2和凋亡促进蛋白bax分别进一步表达下调和上调。［结论］ 对高转移性的上皮性卵巢癌细胞株，Vitamin C和AS2O3单药均具较好的抗肿瘤效应，Vitamin C对AS2O3有较好的化疗增敏效应，两者的联合应用值得在卵巢癌方面进一步研究探讨。 |
| 英文摘要: |
| Abstract：［Purpose］ To investigate the anti-cancer effect of arsenic trioxide(AS2O3) combined with Vitamin C on highly metastatic ovarian carcinoma cell line HO-8910PM.［Methods］ In HO-8910PM cells，the anti-cancer effects of Vitamin C or AS2O3 applied as a single agent were observed，and the sensitizing effects of Vitamin C when it was used in the combination with AS2O3 were observed. The anti-cancer effect of AS2O3 or Vitamin C and their mechanisms were analyzed by MTT chemosensitivity test，flow cytometry and Western-blot method.［Results］ Dose-dependent antiproliferative effect on HO-8910PM cells were observed when Vitamin C or AS2O3 was applied as single agent. Vitamin C had sensitizing effect on AS2O3. Vitamin C combined with AS2O3 leads to significant S-phase block. The expression of inhibitor-of-apoptosis protein bcl-2 was down-regulated，and the promoter of apoptosis protein bax was up-regulated.［Conclusions］ Both AS2O3 and Vitamin C have anti-cancer effects on HO-8910PM cells. Vitamin C has sensitizing effect on Vitamin C when they were used in highly metastatic ovarian carcinoma cells. The combination of the two agents is a promising regimen which is worth on-going study in epithelial ovarian cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|